132 related articles for article (PubMed ID: 12641727)
1. Contribution of two conserved glycine residues to fibrillogenesis of the 106-126 prion protein fragment. Evidence that a soluble variant of the 106-126 peptide is neurotoxic.
Florio T; Paludi D; Villa V; Principe DR; Corsaro A; Millo E; Damonte G; D'Arrigo C; Russo C; Schettini G; Aceto A
J Neurochem; 2003 Apr; 85(1):62-72. PubMed ID: 12641727
[TBL] [Abstract][Full Text] [Related]
2. Prion protein fragment 106-126 induces a p38 MAP kinase-dependent apoptosis in SH-SY5Y neuroblastoma cells independently from the amyloid fibril formation.
Corsaro A; Thellung S; Villa V; Principe DR; Paludi D; Arena S; Millo E; Schettini D; Damonte G; Aceto A; Schettini G; Florio T
Ann N Y Acad Sci; 2003 Dec; 1010():610-22. PubMed ID: 15033801
[TBL] [Abstract][Full Text] [Related]
3. The hydrophobic core sequence modulates the neurotoxic and secondary structure properties of the prion peptide 106-126.
Jobling MF; Stewart LR; White AR; McLean C; Friedhuber A; Maher F; Beyreuther K; Masters CL; Barrow CJ; Collins SJ; Cappai R
J Neurochem; 1999 Oct; 73(4):1557-65. PubMed ID: 10501201
[TBL] [Abstract][Full Text] [Related]
4. The role of prion peptide structure and aggregation in toxicity and membrane binding.
Rymer DL; Good TA
J Neurochem; 2000 Dec; 75(6):2536-45. PubMed ID: 11080207
[TBL] [Abstract][Full Text] [Related]
5. A neurotoxic and gliotrophic fragment of the prion protein increases plasma membrane microviscosity.
Salmona M; Forloni G; Diomede L; Algeri M; De Gioia L; Angeretti N; Giaccone G; Tagliavini F; Bugiani O
Neurobiol Dis; 1997; 4(1):47-57. PubMed ID: 9258911
[TBL] [Abstract][Full Text] [Related]
6. Cytotoxicity of prion protein peptide (PrP106-126) differs in mechanism from the cytotoxic activity of the Alzheimer's disease amyloid peptide, A beta 25-35.
Hope J; Shearman MS; Baxter HC; Chong A; Kelly SM; Price NC
Neurodegeneration; 1996 Mar; 5(1):1-11. PubMed ID: 8731376
[TBL] [Abstract][Full Text] [Related]
7. Molecular characteristics of a protease-resistant, amyloidogenic and neurotoxic peptide homologous to residues 106-126 of the prion protein.
Selvaggini C; De Gioia L; Cantù L; Ghibaudi E; Diomede L; Passerini F; Forloni G; Bugiani O; Tagliavini F; Salmona M
Biochem Biophys Res Commun; 1993 Aug; 194(3):1380-6. PubMed ID: 8102526
[TBL] [Abstract][Full Text] [Related]
8. Conformational polymorphism of the amyloidogenic and neurotoxic peptide homologous to residues 106-126 of the prion protein.
De Gioia L; Selvaggini C; Ghibaudi E; Diomede L; Bugiani O; Forloni G; Tagliavini F; Salmona M
J Biol Chem; 1994 Mar; 269(11):7859-62. PubMed ID: 7907586
[TBL] [Abstract][Full Text] [Related]
9. Molecular determinants of the physicochemical properties of a critical prion protein region comprising residues 106-126.
Salmona M; Malesani P; De Gioia L; Gorla S; Bruschi M; Molinari A; Della Vedova F; Pedrotti B; Marrari MA; Awan T; Bugiani O; Forloni G; Tagliavini F
Biochem J; 1999 Aug; 342 ( Pt 1)(Pt 1):207-14. PubMed ID: 10432318
[TBL] [Abstract][Full Text] [Related]
10. Recombinant human prion protein fragment 90-231, a useful model to study prion neurotoxicity.
Corsaro A; Thellung S; Villa V; Nizzari M; Aceto A; Florio T
OMICS; 2012; 16(1-2):50-9. PubMed ID: 22321015
[TBL] [Abstract][Full Text] [Related]
11. Immunomodulation of the human prion peptide 106-126 aggregation.
Hanan E; Goren O; Eshkenazy M; Solomon B
Biochem Biophys Res Commun; 2001 Jan; 280(1):115-20. PubMed ID: 11162487
[TBL] [Abstract][Full Text] [Related]
12. An unusual soluble beta-turn-rich conformation of prion is involved in fibril formation and toxic to neuronal cells.
Kazlauskaite J; Young A; Gardner CE; Macpherson JV; Vénien-Bryan C; Pinheiro TJ
Biochem Biophys Res Commun; 2005 Mar; 328(1):292-305. PubMed ID: 15670783
[TBL] [Abstract][Full Text] [Related]
13. Highly neurotoxic monomeric α-helical prion protein.
Zhou M; Ottenberg G; Sferrazza GF; Lasmézas CI
Proc Natl Acad Sci U S A; 2012 Feb; 109(8):3113-8. PubMed ID: 22323583
[TBL] [Abstract][Full Text] [Related]
14. The toxicity of prion protein fragment PrP(106-126) is not mediated by membrane permeabilization as shown by a M112W substitution.
Henriques ST; Pattenden LK; Aguilar MI; Castanho MA
Biochemistry; 2009 May; 48(19):4198-208. PubMed ID: 19301918
[TBL] [Abstract][Full Text] [Related]
15. Copper binding to the neurotoxic peptide PrP106-126: thermodynamic and structural studies.
Belosi B; Gaggelli E; Guerrini R; Kozłowski H; Łuczkowski M; Mancini FM; Remelli M; Valensin D; Valensin G
Chembiochem; 2004 Mar; 5(3):349-59. PubMed ID: 14997527
[TBL] [Abstract][Full Text] [Related]
16. Intracellular accumulation of a mild-denatured monomer of the human PrP fragment 90-231, as possible mechanism of its neurotoxic effects.
Chiovitti K; Corsaro A; Thellung S; Villa V; Paludi D; D'Arrigo C; Russo C; Perico A; Ianieri A; Di Cola D; Vergara A; Aceto A; Florio T
J Neurochem; 2007 Dec; 103(6):2597-609. PubMed ID: 17944873
[TBL] [Abstract][Full Text] [Related]
17. Morphology and secondary structure of stable beta-oligomers formed by amyloid peptide PrP(106-126).
Walsh P; Yau J; Simonetti K; Sharpe S
Biochemistry; 2009 Jun; 48(25):5779-81. PubMed ID: 19476383
[TBL] [Abstract][Full Text] [Related]
18. Neurotoxic prion protein (PrP) fragment 106-126 requires the N-terminal half of the hydrophobic region of PrP in the PrP-deficient neuronal cell line.
Sakudo A; Nakamura I; Lee DC; Saeki K; Ikuta K; Onodera T
Protein Pept Lett; 2007; 14(1):1-6. PubMed ID: 17266643
[TBL] [Abstract][Full Text] [Related]
19. High hydrophobic amino acid exposure is responsible of the neurotoxic effects induced by E200K or D202N disease-related mutations of the human prion protein.
Corsaro A; Thellung S; Bucciarelli T; Scotti L; Chiovitti K; Villa V; D'Arrigo C; Aceto A; Florio T
Int J Biochem Cell Biol; 2011 Mar; 43(3):372-82. PubMed ID: 21094273
[TBL] [Abstract][Full Text] [Related]
20. Copper and zinc binding modulates the aggregation and neurotoxic properties of the prion peptide PrP106-126.
Jobling MF; Huang X; Stewart LR; Barnham KJ; Curtain C; Volitakis I; Perugini M; White AR; Cherny RA; Masters CL; Barrow CJ; Collins SJ; Bush AI; Cappai R
Biochemistry; 2001 Jul; 40(27):8073-84. PubMed ID: 11434776
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
